Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance

Sheng Yu Ku,Spencer Rosario,Yanqing Wang,Ping Mu,Mukund Seshadri,Zachary W Goodrich,Maxwell M Goodrich,David P Labbé,Eduardo Cortes Gomez,Jianmin Wang,Henry W Long,Bo Xu,Myles Brown,Massimo Loda,Charles L Sawyers,Leigh Ellis,David W Goodrich,Zachary W. Goodrich,Maxwell M. Goodrich,David P. Labbé,Henry W. Long,Charles L. Sawyers,David W. Goodrich

DOI: https://doi.org/10.1126/science.aah4199

IF: 56.9

2017-01-06

Science

Abstract:Evading cancer drugs by identity fraud Prostate cancer growth is fueled by male hormones called androgens. Drugs targeting the androgen receptor (AR) are initially efficacious, but most tumors eventually become resistant (see the Perspective by Kelly and Balk). Mu et al. found that prostate cancer cells escaped the effects of androgen deprivation therapy through a change in lineage identity. Functional loss of the tumor suppressors TP53 and RB1 promoted a shift from AR-dependent luminal epithelial cells to AR-independent basal-like cells. In related work, Ku et al. found that prostate cancer metastasis, lineage switching, and drug resistance were driven by the combined loss of the same tumor suppressors and were accompanied by increased expression of the epigenetic regulator Ezh2. Ezh2 inhibitors reversed the lineage switch and restored sensitivity to androgen deprivation therapy in experimental models. Science , this issue p. 84 , p. 78 ; see also p. 29

multidisciplinary sciences

What problem does this paper attempt to address?

This paper attempts to address the issues of cell - lineage plasticity, metastasis, and treatment resistance in prostate cancer after anti - androgen therapy. Specifically, the authors investigated the roles of the two genes, Rb1 and Trp53, in suppressing prostate cancer cell - lineage plasticity, metastasis, and resistance to anti - androgen therapy. By constructing a mouse model, the authors found that the deletion of Rb1 promoted the lineage plasticity and metastasis of prostate adenocarcinoma triggered by Pten mutation, and the additional loss of Trp53 led to resistance to androgen - receptor - targeted therapy. These findings revealed the genetic mutations that promote the progression of prostate cancer and suggested the possibility of prolonging the clinical response to androgen - receptor - targeted therapy through epigenetic methods.